Given the critical role of ABC transporters in chemoresistance, our findings may offer insights into a novel therapeutic strategy for overcoming drug resistance in TNBC, potentially improving treatment outcomes for this aggressive breast cancer subtype. This evidence concerns the gene ABCG2 and breast carcinoma.